nevirapine has been researched along with Dyslipidemia in 9 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this cross-sectional observational ('real-world') study was to investigate the effect of three HAART regimens plus stable nevirapine therapy on morphological and metabolic components of lipodystrophy in HIV-infected patients." | 7.77 | Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study. ( Adorni, F; Bagni, P; Carli, F; Garlassi, E; Guaraldi, G; Luzi, K; Menozzi, M; Orlando, G; Stentarelli, C; Zona, S, 2011) |
| "The objective of this cross-sectional observational ('real-world') study was to investigate the effect of three HAART regimens plus stable nevirapine therapy on morphological and metabolic components of lipodystrophy in HIV-infected patients." | 3.77 | Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study. ( Adorni, F; Bagni, P; Carli, F; Garlassi, E; Guaraldi, G; Luzi, K; Menozzi, M; Orlando, G; Stentarelli, C; Zona, S, 2011) |
| " nevirapine on the same background, in naïve HIV-1-infected patients) study compared prospectively ritonavir-boosted atazanavir (ATZ/r) 300 mg/100 mg once daily (qd) with immediate release nevirapine (NVP) 200 mg twice daily or 400 mg qd, each combined with fixed-dose tenofovir 300 mg/emtricitabine 200 mg qd in 569 ARV-naïve HIV-1-infected patients." | 2.76 | Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). ( Andrade-Villanueva, J; Cairns, V; Clotet, B; de Rossi, L; Domingo, P; Gellermann, HJ; Podzamczer, D; Reiss, P; Rockstroh, JK; Soriano, V; Taylor, S, 2011) |
| " This is a retrospective analysis of virologic efficacy and changes in adverse neuropsychiatric effects and serum lipid levels after this switch." | 1.33 | Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. ( Curtin, JM; Ward, DJ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ji, S | 1 |
| Xu, Y | 1 |
| Han, D | 1 |
| Peng, X | 1 |
| Lu, X | 1 |
| Brockmeyer, NH | 1 |
| Wu, N | 1 |
| Pombo, M | 1 |
| Olalla, J | 1 |
| Del Arco, A | 1 |
| De La Torre, J | 1 |
| Urdiales, D | 1 |
| Aguilar, A | 1 |
| Prada, JL | 1 |
| García-Alegría, J | 1 |
| Ruiz-Mateas, F | 1 |
| Bain, AM | 1 |
| White, EA | 1 |
| Rutherford, WS | 1 |
| Rahman, AP | 1 |
| Busti, AJ | 1 |
| Roca, B | 1 |
| Podzamczer, D | 1 |
| Andrade-Villanueva, J | 1 |
| Clotet, B | 1 |
| Taylor, S | 1 |
| Rockstroh, JK | 1 |
| Reiss, P | 1 |
| Domingo, P | 1 |
| Gellermann, HJ | 1 |
| de Rossi, L | 1 |
| Cairns, V | 1 |
| Soriano, V | 1 |
| Guaraldi, G | 1 |
| Zona, S | 1 |
| Orlando, G | 1 |
| Carli, F | 1 |
| Stentarelli, C | 1 |
| Luzi, K | 1 |
| Garlassi, E | 1 |
| Menozzi, M | 1 |
| Bagni, P | 1 |
| Adorni, F | 2 |
| Rosso, R | 1 |
| Rossotti, R | 1 |
| Di Biagio, A | 1 |
| Nicolini, L | 1 |
| Orani, A | 1 |
| Viscoli, C | 1 |
| Ward, DJ | 1 |
| Curtin, JM | 1 |
| Parienti, JJ | 1 |
| Massari, V | 1 |
| Rey, D | 1 |
| Poubeau, P | 1 |
| Verdon, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efavirenz to Nevirapine Switch in HIV-1 Infected Patients With Severe Dyslipidemia: A Randomized Controlled Study[NCT00405171] | Phase 4 | 40 participants | Interventional | 2003-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for nevirapine and Dyslipidemia
| Article | Year |
|---|---|
A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dyslip | 2008 |
Pharmacogenomics of antiretrovirals.
Topics: Alkynes; Anti-Retroviral Agents; Aryl Hydrocarbon Hydroxylases; Atazanavir Sulfate; Benzoxazines; Ce | 2008 |
2 trials available for nevirapine and Dyslipidemia
| Article | Year |
|---|---|
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Dyslipidemia | 2011 |
Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study.
Topics: Alkynes; Benzoxazines; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Cyclopropanes; Dose-R | 2007 |
5 other studies available for nevirapine and Dyslipidemia
| Article | Year |
|---|---|
Changes in Lipid Indices in HIV+ Cases on HAART.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cholesterol, HDL; Cholesterol, LDL; Dia | 2019 |
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carba | 2013 |
Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Body Fat Dist | 2011 |
Nevirapine-based regimens in routine clinical settings: results from a large Italian cohort of HIV-1 infected adults.
Topics: Adult; Age Factors; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol; Cohort Studies; Databa | 2011 |
Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Dyslipidemias; Female; HIV Infections; Humans; Lipids; | 2006 |